Brokerage : SK Securities
Analyst : Seonkyoung Lee
Investment Rating : BUY (Maintained)
Target Price : KRW 247,823 (Maintained)
Core Momentum : Operating leverage begins in earnest as high-margin new products expand to 65% of total sales, delivering a strong 2Q26 earnings beat with sustained growth expected from Zymfentra’s Pfizer collaboration and Omlyclo’s US launch.
📊 1. [Valuation & Key Financial Metrics]
- Rating & Target Price: BUY (Maintained) / Target Price KRW 247,823 (Maintained) (Upside potential of 32.7% based on the July 31, 2026 closing price of KRW 186,700)
- Market Data: KOSPI Index 6,595.45pt / Market Cap KRW 43.42 Trillion / Shares Outstanding 232.55 Million / 52-Week High KRW 236,862 / 60-Day Average Trading Value KRW 131.0 Billion / Foreign Ownership 24.79% / Major Shareholders: Celltrion Holdings and 95 affiliates 32.83%, National Pension Service 6.67%
- 2Q26 Financial Review (Actual vs Consensus):
- Revenue: KRW 1.39 Trillion (+45.0% YoY, +21.7% QoQ, beating consensus of KRW 1.24 Trillion by +12.1%)
- Operating Profit: KRW 451.8 Billion (+86.3% YoY, +40.4% QoQ, OPM 32.4%, beating consensus of KRW 400.7 Billion by +12.7%)
- Net Profit (Controlling): KRW 362.0 Billion (beating consensus of KRW 326.0 Billion by +11.0%, controlling net margin 26.0%)
- Annual Financial Forecast (SK Securities Revised Estimates):
- 2026F Revenue: KRW 5.56 Trillion (+33.6% YoY, raised by +4.8% vs previous estimate, beating consensus of KRW 5.30 Trillion by +5.0%)
- 2026F Operating Profit: KRW 1.78 Trillion (+52.7% YoY, OPM 32.1%, raised by +2.9% vs previous estimate, beating consensus of KRW 1.76 Trillion by +1.7%)
- 2026F Net Profit (Controlling): KRW 1.53 Trillion (controlling net margin 27.5%, raised by +7.1% vs previous estimate, beating consensus of KRW 1.46 Trillion by +5.1%)
🚀 2. [Market Opportunities & Business Outlook]
- Operating Leverage Acceleration & 2Q26 Earnings Beat:
- Driven by solid expansion in legacy products (KRW 439.0 Billion, +5.8% YoY, +11.7% QoQ) and surging sales of high-margin new products (KRW 824.9 Billion, +76.3% YoY, +41.9% QoQ).
- High-margin new products accounted for 65% of total sales, triggering significant operating leverage that lifted OPM to 32.4% (+7.2%p YoY, +4.3%p QoQ) despite increased SG&A expenses (KRW 412.4 Billion, +36.6% YoY, +13.3% QoQ).
- Key Product Dynamics & US Market Expansion:
- Yuflyma: Posted revenue of KRW 195.4 Billion (+42.2% YoY, +71.3% QoQ), propelled by expanding US market share following the transition to a Low WAC pricing strategy.
- Zymfentra: Recorded revenue of KRW 46.7 Billion (+106.6% YoY, -11.6% QoQ) as ongoing prescription volume growth was partially offset by a one-off rebate settlement adjustment in Q2.
- Positive Second-Half Outlook & Fixed-Cost Leverage:
- In addition to stable growth across new product lines, Zymfentra is expected to accelerate via its co-promotion partnership with Pfizer, alongside the upcoming commercial US launch of Omlyclo.
- Expanding revenues from high-margin assets will reinforce fixed-cost leverage, sustaining profitability improvements throughout H2 2026.
📝 Editor’s Comment (Perspective)
The analyst views Celltrion as entering an active operating leverage phase, where the expansion of high-margin new products to 65% of total revenues offsets rising SG&A expenses and drives meaningful profitability improvement. The overarching perspective prioritizes top-line growth and ongoing profitability gains across the second half—supported by Yuflyma’s US market share gains, Zymfentra’s collaboration with Pfizer, and Omlyclo’s impending US rollout—over temporary quarterly rebate settlement adjustments.
To verify whether this investment thesis progresses as expected, investors should primarily monitor the ramp-up in US Zymfentra prescription sales supported by Pfizer’s sales force, the official US commercial launch and initial uptake of Omlyclo in H2, sustained market share gains for Yuflyma in the US, and the maintenance of full-year operating profit margins above 32%. These developments can be verified through upcoming quarterly earnings releases, official company IR presentations, and regulatory filings on DART.
📢 Disclaimer & Source
Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)
